Author of

• 20182

  +

  P3.03 - Chemotherapy/Targeted Therapy (ID 719)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24048

    +

    P3.03-003 - ABCB1 3435C≫T Polymorphism Influences the Toxicity and Clinical Outcome of Patients with Taxane-Based Chemotherapy (ID 8071)

    09:30 - 09:30  |  Author(s): L. Fan
    • Abstract

    Background:
    Taxane-based chemotherapy including paclitaxel, docetaxel, paclitaxel-albumin was wildly used in solid tumors. ABCB1 (P-glycoprotein, multidrug resistance 1) is a trans-membrane protein that acts as an energy-dependent drug efflux pump for chemotherapeutic drugs, including taxanes. In addition, ABCB1 has been suggested to have a role in the prediction of treatment response and toxicity of chemotherapy in breast cancer, gastric cancer et.al. In this retrospective study, we explore the influence of ABCB1 polymorphism on toxicity and taxane-based chemotherapy.
    
    Method:
    118 patients (lung cancer 103, others 15) with taxane-based chemotherapy (paclitaxel 56 cases, docetaxel 55 cases, paclitaxel-albumin 7 cases) treatment were included in this study. Fluorescence in situ hybridization (FISH) was used for ABCB1 polymorphism detection. Statistical analysis was performed using SPSS 20.0.
    
    Result:
    The frequency of the ABCB1 3435 site homozygous mutation (TT genotype), heterozygous mutation (TC genotype) and wild type (CC genotype) was 11.0%(13/118) , 45.8%(54/118) and 43.2%(51/118) respectively. The occurrence of neurotoxicity was higher in patients had TT genotype (62.9%) compared with patients had TC (25.9%) and CC genotype (37.3%)(P=0.310). Especially in the docetaxol subgroup, the difference of chemotherapy-induced neurotoxicity was statistically significant (TT 75.0%, TC 9.5%, CC 11.5%, P=0.007). There was not significant difference between the three ABCB1 genotypes with regarding to other chemotherapy-induced toxicity, including diarrhea, constipation, leukocytes, neutrophils, anemia and thrombocytopenia. For non-small cell lung cancer (NSCLC) patients in this study, patient harboring ABCB1 3435 site CC genotype had longer median progression free survival (PFS) (5.1 months) than TC genotype (4.7 months) and TT genotype (2.6 months)(P=0.42). Especially in the paclitaxel subgroup (n=21), the median progression was significantly longer in patients with CC genotype when compared with TC and TT genotype (9.8 months vs. 4.5 months vs. 1.6 month, P=0.06). We failed to find the difference in either response rate or disease control rate between the different genotype, even in subgroup analysis.
    
    Conclusion:
    ABCB1 3435 site polymorphism is associated with neurotoxicity of taxane-based chemotherapy. It can also predict clinical outcomes for NSCLC.